Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-23
2008-10-07
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S130100
Reexamination Certificate
active
07432244
ABSTRACT:
Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers.
REFERENCES:
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5342763 (1994-08-01), Swartz
patent: 5470828 (1995-11-01), Ballard et al.
patent: 2002/0165155 (2002-11-01), Schaffer et al.
patent: 0 294 021 (1988-04-01), None
patent: 0 369 943 (1989-11-01), None
patent: 0 375 438 (1989-12-01), None
patent: 742228 (1996-11-01), None
patent: WO 89/09792 (1988-06-01), None
patent: WO 89/08667 (1989-03-01), None
patent: WO 89/09268 (1989-03-01), None
patent: WO 91/03253 (1991-03-01), None
patent: WO 93/23067 (1993-11-01), None
patent: WO 93/23071 (1993-11-01), None
patent: WO 94/04569 (1994-03-01), None
patent: WO 96/33216 (1996-10-01), None
patent: WO 98/45427 (1998-10-01), None
patent: WO 99/38011 (1999-07-01), None
patent: WO 00/23469 (2000-04-01), None
patent: WO 01/25790 (2001-04-01), None
patent: WO 01/72771 (2001-10-01), None
Baxter, Robert C., “The Insulin-Like Growth Factors and Their Binding Proteins”, Comp. Biochem. Physiol., vol. 91B, pp. 229-235, 1988.
Baxter, Robert C., et al., “Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum Comparison with Other Human and Rat Binding Proteins”, Biochemical and Biophysical Research Communication, vol. 147, pp. 408-415, 1987.
Binkert, C., et al., Cloning, Sequence Analysis and Expression of a cDNA Encoding a Novel Insulin-Like Growth Factor Binding Protein (IGFBP-2), EMBO J., vol. 8; pp. 2497-2502, 1989.
Brewer, Michael T., et al., “Cloning, Characterization and Expression of a Human Insulin-Like Growth Factor Binding Protein”, Biochemical and Biophysical Research Communication, vol. 152, pp. 1289-1297, 1988.
Brinkman, A., et al., “Isolation and Characterization of a cDNA Encoding the Low Molecular Weight Insulin-Like Growth Factor Binding Protein (IBP-1)”, The EMBO Journal, vol. 7, pp. 2417-2423, 1988.
Dennis, Mark S., et al., “Peptide Exosite Inhibitors of Factor VIIa as Anticoagulants”, Nature, vol. 404, pp. 465-470, 2000.
Grupe, Andrew, et al., Inhibition of Insulin receptor Phosphorylation by PC-1 Is Not Mediated by the Hydrolysis of Adenosine Triphosphate or the Generation of Adenosine J. Biol. Chem., vol. 270, pp. 22085-22088, 1995.
Jin, Lei, et al., “High Resolution Functional Analysis of Antibody-Antigen Interactions”, J. Mol. Biol., vol. 226, pp. 851-865, 1992.
Lassalle, Phillppe, et al., “ESM-1 Is a Novel Human Endothelial Cell-Specific Molecule Expressed in Lung and Regulated by Cytokines”, J. Biol. Chem., vol. 271, pp. 20458-20464, 1996.
Lee, Yao-Ling, et al., “Insulin-Like Growth Factor (IGF) Binding Protein Complementary Deoxyribonucleic Acid from Human HEP G2 Hepatoma Cells: Predicted Protein Sequence Suggests and IGF Binding Domain Different from Those of the IGF-I and IGF-II Receptors”, Mol. Endocrinal., vol. 2, pp. 404-411, 1988.
Leung, David, et al., “Growth Hormone Receptor and Serum Binding Protein: Purification, Cloning and Expression”, Nature 330, pp. 537-543, 1987.
Martin, Janet L., et al., “Insulin-like Growth Factor-binding Protein from Human Plasma”, J. Biol. Chem., vol. 261, pp. 8754-8760, 1986.
Oh, Youngman, et al., “Synthesis and Characterization of Insulin-like Growth Factor-Binding Protein (IGFBP)-7”, J. Biol. Chem., vol. 271, pp. 30322-30325, 1996.
Sidhu, Sachdev S., et al., “Phage Display for Selection of Novel Binding Peptides”, Methods in Enzymology, vol. 328, pp. 333-363, 2000.
Swisshelm, Karen, et al., “Enhanced Expression of an Insulin Growth Factor-like Binding Protein (mac25) in Senescent Human Mammary Epitherlial Cells and Induced Expression with Retinoic Acid”, Proc. Nat. Sci. USA, vol. 92, pp. 4472-4476, 1995.
Wood, William I., et al., “Cloning and Expression of the Growth Hormone-Dependent Insulin-Like Growth Factor-Binding Protein”, Molecular Endocrinology, vol. 2, pp. 1176-1185, 1988.
Yamauchi, Teruaki, et al., “Purification and Molecular Cloning of Prostacyclin-Stimulating Factor from Serum-free Conditioned Medium of Human Diploid Fibroblast Cells”, Pro Biochemical Journal, vol. 303, pp. 591-598, 1994.
Bach and Rechler., “Insulin-Like Growth Factor Binding Proteins.”Diabetes Reviews. 3(1):38-61 (1995).
Ballard et al., “Does IGF-I Ever Act Through the Insulin Receptor?”The Insulin-Like Growth Factors and Their Regulatory Proteins., Baxter, eds., Amsterdam: Elsevier pp. 131-138 (1994).
Bar et al., “Tissue Localization of Perfused Endothelial Cell IGF Binding Protein is Markedly Altered by Association with IGF-I.”Endocrinology, 127(6):3243-3245 (1990).
Baserga., “The Insulin-Like Growth Factor 1 Receptor: A Key to Tumor Growth?”Cancer Research55:249-252 (Jan. 1995).
Baxter., “The Somatomedins: Insulin-Like Growth Factors.”Advances in Clinical Chemistry, 25:49-115 (1986).
Bayne et al., “Structural Analogs of Human Insulin-Like Growth Factor I with Reduced Affinity for Serum Binding Proteins and the Type 2 Insulin-Like Growth Factor Receptor.”J. Bio. Chem. 263:6233-6239 (1988).
Bayne et al., “The C Region of Human Insulin-Like Growth Factor (IGF) I is Required for High Affinity Binding to the Type 1 IGF Receptor.”J. Bio. Chem. 264(19):11004-11008 (1988).
Bayne et al., “The Roles of Tyrosines 24, 31, and 60 in the High Affinity Binding of Insulin-Like Growth Factor-I to the Type I Insulin-Like Growth Factor Receptor.”J. Bio. Chem. 265(26):15648-15652 (Sep. 15, 1990).
Binoux, M., “Recent Data on Somatomedins (Insulin-Like Growth Factors) .”Annales d'Endocrinologie(English Abstract Included) 41:157-192 (1980).
Blundell et al., “Insulin-Like Growth Factor: A Model for Tertiary Structure Accounting for Immunoreactivity and Receptor Binding.”Proc. Natl. Acad. Sci. USA 75(1):180-184 (Jan. 1978).
Blundell et al., “Tertiary Structures, Receptor Binding, and Antigenicity of Insulinlike Growth Factors.”Federation Proc. 42:2592-2597 (1983).
Buckbinder et al., “Induction of the Growth Inhibitor IGF-Binding Protein 3 by p53.”Nature. 377:646-649 (Oct. 1995).
Cascieri et al., “Mutants of Human Insulin-Like Growth Factor I with Reduced Affinity for the Type 1 Insulin-Like Growth Factor Receptor.”Biochemistry27(9):3229-3233 (May 3, 1988).
Cascieri et al., “Structural Analogs of Human Insulin-Like Growth Factor (IGF) I with Altered Affinity for Type 2 IGF Receptors.”J. Bio. Chem. 264:2199-2202 (1989).
Clemmons and Van Wyk., “Somatomedin: Physiological Control and Effects on Cell Proliferation.”Handbook Exp. Pharmacol. 57:161-208 (1981).
Clemmons et al., “Discrete Alterations of the Insulin-Like Growth Factor I Molecule Which Alter Its Affinity for Insulin-Like Growth Factor-Binding Proteins Result in Changes in Bioactivity.”J. Bio. Chem. 265(21):12210-12216 (1990).
Clemmons et al., “The Role of Insulin-Like Growth Factor Binding Proteins in Modifying IGF Actions.”Anal. NY Acad. Sci. USA 692:10-21 (1993).
Cohen and Ellwein., “Cell Proliferation in Carcinogenesis.”Science. 249:1007-1011 (Aug. 1990).
Cohen and Ellwein., “Genetic Errors, Cell Proliferation, and Carcinogenesis.”Cancer Research. 51:6493-6505 (Dec. 1991).
Cohen et al., “Biological Effects of Prostate Specific Antigen as an Insulin-Like Growth Factor Binding Protein-3 Protease.”J. Endocrinology. 142:407-415 (1994).
Cohen et al., “Insulin-Like Growth Factors (IGFs) , IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells.”J. Clin. Endocrin.&Metab.
Deshayes Kurt D.
Lowman Henry B.
Schaffer Michelle L.
Sidhu Sachdev S.
Dreger Ginger R.
Fox James A.
Genentech Inc.
Kresnak Mark T.
Saoud Christine J
LandOfFree
Method of inhibiting insulin-like growth factor-1 (IGF-1) by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting insulin-like growth factor-1 (IGF-1) by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting insulin-like growth factor-1 (IGF-1) by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015561